Astellas Pharma Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.